8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 22, 2026·SEC
MindMed is currently in a high-stakes, pre-revenue development phase, with its valuation heavily contingent on the successful progression of the MM-120 candidate through Phase 3 clinical trials. While the company maintains a $262.5 million cash position, the r...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 5, 2026 | -$0.51-6.3% vs -$0.48 | — vs — |
Q1 2026 Feb 26, 2026 | -$0.56-16.7% vs -$0.48 | — vs — |
Q4 2025 Nov 6, 2025 | -$0.78-50.0% vs -$0.52 | — vs — |
Q3 2025 Jul 31, 2025 | -$0.50-31.6% vs -$0.38 | — vs — |
Benchmark MNMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mind Medicine (MindMed) Inc. (MNMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $42.79 | $3.23B | -20.77 | — | — | -64.06% | — | |
| $13.75 | $1.86B | -4.46 | — | — | -398.21% | — | |
| $7.35 | $2.72B | -2.53 | 1227.6% | -14938.37% | -353.02% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $0.46 | $7.8M | -0.22 | -25.96% | -4791.48% | -106.13% | — | |
| $1.77 | $2M | -0.24 | — | -8269.53% | -81.74% | — |
Mind Medicine (MindMed) Inc. (MNMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mind Medicine (MindMed) Inc. (MNMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 12, 2026·SEC
May 7, 2026·SEC
Apr 22, 2026·SEC
Get notified when MNMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mind Medicine (MindMed) Inc. (MNMD) stock FAQ — growth, dividends, profitability & financials explained
Mind Medicine (MindMed) Inc. (MNMD) reported a net loss of $237.5M for fiscal year 2025.
Mind Medicine (MindMed) Inc. (MNMD) has a return on equity (ROE) of -64.1%. Negative ROE indicates the company is unprofitable.
Mind Medicine (MindMed) Inc. (MNMD) had negative free cash flow of $174.3M in fiscal year 2025, likely due to heavy capital investments.